NCT07136454View on ClinicalTrials.gov

Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome

AVAILABLEEXPANDED_ACCESS

Timeline

Start Date

Not specified

Conditions

Angelman Syndrome

Interventions

DRUG

Rugonersen

Rugonersen is a selective synthetic 20-mer antisense oligonucleotide (ASO).

Sponsors

Lead Sponsor

Oak Hill Bio Ltd

All Listed Sponsors

collaborator

Early Access Care LLC

UNKNOWN

lead

Oak Hill Bio Ltd

INDUSTRY

NCT07136454 - Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome | Biotech Hunter | Biotech Hunter